Current Reviews in Clinical and Experimental Pharmacology最新文献

{"title":"Fisetin, a Promising Anti-Cancer Flavonoid: A Brief Review of Its Biological Effects and Molecular Mechanisms in Lung Cancer Prevention and Therapy.","authors":"Ali Jahanban-Esfahlan, Parina Asgharian, Samin Mohammadi, Hadi Ghanbari, Solmaz Asnaashari","doi":"10.2174/0127724328344902250324062309","DOIUrl":"10.2174/0127724328344902250324062309","url":null,"abstract":"<p><strong>Introduction: </strong>Experimental evidence has demonstrated that compounds of natural origin possess adjuvant anti-cancer properties, and their combination with anti-cancer drugs has the potential to reduce drug resistance in cancer treatment exhibiting chemoprotective effects.</p><p><strong>Methods: </strong>Fisetin (FIS), a flavonoid-structured polyphenolic compound found in various vegetables and fruits, is used as a yellow/ochre coloring agent and shows diverse pharmacological and biological effects. FIS can modulate various signaling pathways in relation to oxidative stress, inflammation, cell proliferation, metastasis, and angiogenesis. Thus, FIS is proposed to be a beneficial agent for preventing and treating numerous human malignancies. Awareness of natural compound action mechanisms paves the way for scientific communities, healthcare organizations, and the pharmaceutical industry to develop and introduce new drugs to treat diseases. In this paper, the general properties of FIS were highlighted first, and later, using the Scopus database, all related scientific literature regarding the studies that investigated the effects of FIS on lung cancer was collected.</p><p><strong>Results: </strong>The critical points were extracted from the research works, and possible effects and molecular mechanisms of FIS on cancer cells were reviewed, and a comprehensive discussion about the roles of this phytochemical on different signaling pathways that were very crucial in lung cancer cells was provided.</p><p><strong>Conclusion: </strong>Finally, the current challenges and future perspectives of lung cancer prevention and therapy approaches using FIS were addressed.</p>","PeriodicalId":29871,"journal":{"name":"Current Reviews in Clinical and Experimental Pharmacology","volume":" ","pages":"52-74"},"PeriodicalIF":0.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143796591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Current Reviews in Clinical and Experimental Pharmacology (CRCEP)-Preface-2026.","authors":"Arduino A Mangoni","doi":"10.2174/0127724328452067251106080641","DOIUrl":"10.2174/0127724328452067251106080641","url":null,"abstract":"","PeriodicalId":29871,"journal":{"name":"Current Reviews in Clinical and Experimental Pharmacology","volume":" ","pages":"iv"},"PeriodicalIF":0.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145557514","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nanotechnology: A Potentially Powerful Tool for Attenuating Cisplatin- Induced Nephrotoxicity: A Narrative Review.","authors":"Hasan Ebrahimi Shahmabadi, Tahereh Zadeh Mehrizi, Mehdi Shafiee Ardestani","doi":"10.2174/0127724328374568250711183328","DOIUrl":"10.2174/0127724328374568250711183328","url":null,"abstract":"<p><p>Cis-diamminedichloroplatinum (II) (cisplatin, CDDP) is one of the main anticancer drugs, used for the treatment of various malignancies. However, clinical application of this drug is associated with various side effects, prominently nephrotoxicity. One of the promising tools to decrease the side effects of the drug and simultaneously improve its therapeutic effects is the loading the drug into nanoparticles (NPs). This literature review focuses on the efficacy of various types of NPs, such as liposome, micelle, dendrimer, poly (lactic-co-glycolic acid), chitosan, alginate, curcumin (CUR), and metallic NPs to improve the therapeutic effects of CDDP and to decrease the nephrotoxicity. The results of these studies demonstrated that the reviewed NPs are able to decrease the nephrotoxic effects of CDDP in one of four different ways, including as a conjugating agent, encapsulating agent, antioxidant agent, or nanocarrier. Finally, among these reviewed NPs, liposomal NPs and the co-treatment with CUR as an antioxidant agent have more promising effects in reducing the toxicity of CDDP. Overall, the wide use of nanoliposomes in drug delivery systems due to their high stability, biocompatibility, drug loading capacity, and high bioavailability prompts the authors to propose liposomal CDDP delivery as a potent candidate for future studies. Moreover, because of the synergistic effects of CUR and CDDP on cancerous cells, the antioxidative properties of CUR in mitigating CDDP-induced nephrotoxicity, and the radiosensitizing influence of CUR, there is potential for the co-delivery of CDDP and CUR via liposomes to the tumor region.</p>","PeriodicalId":29871,"journal":{"name":"Current Reviews in Clinical and Experimental Pharmacology","volume":" ","pages":"201-227"},"PeriodicalIF":2.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144745276","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Use of Different Local Anesthetics in Pregnant Women in Dentistry: A Systematic Review.","authors":"Yasmin Gabrielly Miranda da Cunha, Eloiza Ferreira da Silva, Gabriela M Oliveira, Carlos F Santos, Adriana M Calvo","doi":"10.2174/0127724328349965250407082245","DOIUrl":"10.2174/0127724328349965250407082245","url":null,"abstract":"<p><strong>Background: </strong>Despite the potential side effects of local anesthetics, they are indispensable for relieving pain and, consequently, reducing the patient's stress.</p><p><strong>Objective: </strong>The objective of the present research was to evaluate, through a systematic review, the different types of local anesthetics available for use in dental procedures in pregnant patients.</p><p><strong>Methods: </strong>Electronic bibliographic searches were conducted to retrieve studies published from 2000 to 2024 concerning the use of local anesthetics in pregnant women in dentistry. Five studies were included in this review (2 case series, 2 cohort studies, and 1 randomized clinical trial).</p><p><strong>Results: </strong>The studies involved a total of 1,954 patients. The primary local anesthetic used was lidocaine with epinephrine/adrenaline. There were no significant differences in pregnant women who received local anesthesia regarding gestational age at delivery, birth weight of the baby, induction of labor pain, preterm birth delivery, spontaneous abortions, stillbirths, fetal anomalies, risk of experiencing serious medical adverse events or adverse pregnancy outcomes. A limited number of studies were identified, and the information was restricted.</p><p><strong>Conclusion: </strong>Both the present review and previous studies support the lack of grounds to avoid providing dental care and using local anesthetics during pregnancy.</p>","PeriodicalId":29871,"journal":{"name":"Current Reviews in Clinical and Experimental Pharmacology","volume":" ","pages":"133-146"},"PeriodicalIF":2.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143989282","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Significance of Model-Based Strategies in Drug Development throughout the Lifecycle and Regulatory Decision-Making.","authors":"Maitry Suthar, Neha Dandekar, Dipti Patel, Drashti Shah","doi":"10.2174/0127724328406757251204044645","DOIUrl":"10.2174/0127724328406757251204044645","url":null,"abstract":"<p><strong>Introduction: </strong>Model-informed drug development (MIDD) is a regulatory-endorsed approach that streamlines drug discovery, development, and approval. Actively promoted by the U.S. Food and Drug Administration (FDA), it integrates quantitative modelling to support decisionmaking across drugs, generics, and biologics.</p><p><strong>Objectives: </strong>This study aims to highlight the applications, benefits, and future perspectives of MIDD in optimizing clinical trial design, supporting regulatory review, advancing biopharmaceutics, and enabling innovation in emerging therapeutic areas.</p><p><strong>Methods: </strong>Current applications of MIDD were evaluated, focusing on its role in new drug development, generic drug approval, biopharmaceutics, and early exploration in cell and gene therapy. The study emphasizes computational modelling, dose optimization, clinical trial refinement, and postapproval lifecycle management strategies.</p><p><strong>Results and discussion: </strong>MIDD has demonstrated considerable impact in optimizing dose selection, refining trial design, and addressing regulatory concerns regarding efficacy and safety. In the field of biopharmaceutics, computational modelling has guided formulation development and facilitated subsequent in vivo studies. In genetics, mathematical modelling has enabled efficient development and approval of complex formulations, reducing both time and cost. MIDD shows strong potential for quantitatively analysing biological activity, pharmacodynamics, transgene expression, immune responses, safety, and therapeutic effectiveness.</p><p><strong>Conclusion: </strong>MIDD is a transformative approach in drug development, offering robust tools for decision- making and regulatory assessment. Its broader implications across therapeutic domains are expected to enhance innovation, improve patient outcomes, and reduce development costs. Future advancements, particularly in cell and gene therapy, will further expand its role as a cornerstone of drug development.</p>","PeriodicalId":29871,"journal":{"name":"Current Reviews in Clinical and Experimental Pharmacology","volume":" ","pages":"290-302"},"PeriodicalIF":2.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147460390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pharmacogenetics of Statin-Induced Myopathy: Genetic Gatekeepers Shaping Precision Therapeutics.","authors":"Ali H Eid","doi":"10.2174/0127724328452142251110050640","DOIUrl":"10.2174/0127724328452142251110050640","url":null,"abstract":"","PeriodicalId":29871,"journal":{"name":"Current Reviews in Clinical and Experimental Pharmacology","volume":" ","pages":"92-95"},"PeriodicalIF":0.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145557778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anti-obesity Treatments with Anti-inflammatory and Antioxidant Potential and their Effects on Obesity-related Metabolic and Cardiovascular Disorders: A Narrative Review.","authors":"Fani-Niki Varra, Michail Varras, Viktoria-Konstantina Varra, Panagiotis Theodosis-Nobelos","doi":"10.2174/0127724328392698250818071803","DOIUrl":"10.2174/0127724328392698250818071803","url":null,"abstract":"<p><strong>Introduction: </strong>Obesity is a condition that affects a large part of the global population, and especially in the Western world, leading to a significant systemic inflammatory response in the body, characterized by modification of the secretory inflammatory cytokines and adipokines. The combination of fat accumulation and inflammation can lead to concomitant conditions, such as Insulin Resistance (IR) and increased production and release of fatty acids, ultimately enhancing the occurrence of conditions like metabolic and cardiovascular disorders, with inflammation and oxidative stress being implicated in these phenomena and appearing as important interconnecting factors. In this review, an attempt is made to analyze, in terms of their full scope of action, the pharmaceutical approaches against obesity, which affect fats, sugars, adipokines, and also the central nervous system.</p><p><strong>Methods: </strong>Using data from experimental animal procedures and clinical trials, the involvement of anti-obesity drugs against systemic chronic inflammation and oxidative stress, as well as in obesityrelated cardiometabolic disorders, is analyzed.</p><p><strong>Results: </strong>Anti-obesity treatments targeting more than one factor at the mechanistic level and limiting the body's inflammatory responses could contribute in multiple ways to improving metabolic and cardiovascular conditions and derangements. However, they carry a high risk of adverse effects, which may be reduced with the combination of such treatments, leading to a more favorable activity- to-hazard ratio and elucidation of the complete mechanistic properties of these treatments.</p><p><strong>Discussion: </strong>Until now, many gaps in the literature remain concerning one or more of these aspects for all these treatments. Through the prism of the multi-functional nature of these compounds, an attempt is made to clarify the multi-level nature of action of these substances against obesity, potentially allowing limiting the multi-drug treatment of these conditions, leading to the limitation of interactions, and the multiple side effects related to the drug combination.</p><p><strong>Conclusion: </strong>In order to achieve the above-mentioned objectives, in addition to investigating the full range of action of these anti-obesity drug treatments, the full history of their dose-dependent side effects and contraindications is required, through further clinical studies and analyses. These findings will shed light on the complete anti-inflammatory, antioxidant, and metabolic changes that anti-obesity treatments could offer, and the clinical manipulation of conditions associated with obesity, since the current misalignment and, in some cases, the mixed results between the already existing research groups lead to less definite conclusions.</p>","PeriodicalId":29871,"journal":{"name":"Current Reviews in Clinical and Experimental Pharmacology","volume":" ","pages":"97-116"},"PeriodicalIF":2.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144971978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mechanistic Effects and Complications of Berberine on Cardiac Arrhythmias: A Systematic Review.","authors":"Shahab Masoumi, Mohammadreza Moetazedian, Samira Jafari, Saeid Heidari-Soureshjani, Catherine Mt Sherwin","doi":"10.2174/0127724328346501250404175826","DOIUrl":"10.2174/0127724328346501250404175826","url":null,"abstract":"<p><strong>Background: </strong>Arrhythmia is an abnormal sinus rhythm of the heartbeat, and in addition to threatening the patient's health, it may also cause fatal complications.</p><p><strong>Objectives: </strong>The present review study was investigated the effects of berberine (BBR) on cardiac arrhythmias and its possible complications.</p><p><strong>Methods: </strong>A systematic search was conducted on electronic databases such as PubMed/MEDLINE, Web of Science, Scopus, Embase, and Cochrane Library to identify relevant studies published before June 10, 2024. Inclusion criteria were defined based on the study's aim. Two reviewers performed data extraction independently to ensure accuracy and minimize bias. The data were finally extracted and analyzed.</p><p><strong>Results: </strong>Finally, 22 studies were included. BBR revealed antiarrhythmic effects through antioxidant, anti-inflammatory, and anti-apoptotic activity and improved mitochondrial function. Moreover, BBR modulated ion channels and improved electrical remodeling trough inhibited Potassium current (I_K), I_K1, I_Kr, I_Ks, I_Ca, I_Na, K_ATP channels and human ether-a-go-go related gene (hERG) and improved expression of inwardly rectifying potassium (Kir)6.2 and Kir2.1. It also increased action potential duration (APD), prolonged the effective refractory period (ERP), and reduced the frequency and complexity of ventricular premature complexes (VPC). However, it causes some cardiovascular side effects, including prolonged QT interval, bradycardia, and hypotensive effects. BBR may also lead to gastrointestinal complications, immunosuppressive effects, and interaction with concomitant drugs.</p><p><strong>Conclusion: </strong>Although BBR's cardioprotective properties have satisfactory effects on cardiac arrhythmia, it causes prolonged QT interval, bradycardia, hypotension, and cardiotoxicity. However, more clinical studies are needed to obtain more reliable results.</p>","PeriodicalId":29871,"journal":{"name":"Current Reviews in Clinical and Experimental Pharmacology","volume":" ","pages":"117-132"},"PeriodicalIF":2.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144015202","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Gut Connection: A Narrative Review on the In-depth Analysis of Gut Microbiota and Metabolites in Depression.","authors":"Ayesha Sultana, Md Sadique Hussain, Mudasir Maqbool, Mohit Agrawal, Ajay Singh Bisht, Navneet Khurana, Gurvinder Singh, Rajesh Kumar","doi":"10.2174/0127724328332998250118182255","DOIUrl":"10.2174/0127724328332998250118182255","url":null,"abstract":"<p><p>Depression is a prevalent mood disorder with significant public health implications. Despite extensive research, its precise causes remain inadequately understood. Recently, interest has surged in the role of the gut microbiome and its metabolites in the pathophysiology of depression. This review aims to provide a comprehensive overview of the relationship between gut microbiota, its metabolites, and depression while exploring potential mechanisms influencing the efficacy of antidepressant medications. A narrative review methodology was employed, synthesizing recent studies utilizing a multi-omics approach. We examined alterations in gut microbiome composition and metabolite production in individuals diagnosed with depression, discussing the technical tools and methods commonly applied in this research area. The findings indicate that individuals with depression show significant alterations in gut microbiome composition, notably an imbalance in <i>Firmicutes, Bacteroidetes</i>, and <i>Actinobacteria</i>. Changes in metabolite production, including short-chain fatty acids, tryptophan, and bile acids, were also observed. Moreover, the review highlights that antidepressant medications may exert their therapeutic effects by modulating gut microbiota and its metabolites. This review emphasizes the intricate interplay between gut microbiota, its metabolites, and depression, revealing critical insights into the mechanisms underlying antidepressant efficacy. We recommend that future research focus on elucidating these interactions to develop innovative therapeutic strategies, potentially transforming the management of depression through microbiota-targeted approaches.</p>","PeriodicalId":29871,"journal":{"name":"Current Reviews in Clinical and Experimental Pharmacology","volume":" ","pages":"25-51"},"PeriodicalIF":0.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143123792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pharmacological Perspectives on Curcumin in Osteomyelitis: Molecular Mechanisms, Antibacterial Synergy, and Bone-Regenerative Potential.","authors":"Solmaz Maleki Dizaj, Mohammad Yousef Memar, Simin Sharifi, Khadijeh Khezri, Amir Zandesh, Sara Ghadaksaz, Pouya Sabanik","doi":"10.2174/0127724328438840251210104637","DOIUrl":"10.2174/0127724328438840251210104637","url":null,"abstract":"<p><p>Osteomyelitis is difficult to treat due to biofilm persistence, limited antibiotic penetration, and increasing resistance. Curcumin, a pleiotropic polyphenol from Curcuma longa, shows convergent activity relevant to bone infection: (i) anti-biofilm and quorum-sensing inhibition, (ii) antibiotic synergy via efflux-pump modulation and membrane permeabilization, (iii) suppression of inflammatory pathways that drive osteoclastogenesis, and (iv) pro-osteogenic effects that support repair. In preclinical models, curcumin and select nanoformulations enhance bacterial clearance, reduce inflammatory osteolysis, and improve osteoblast function; device-related infection models also report decreased biofilm burden when curcumin is combined with standard antibiotics. Pharmacokinetic limitations of free curcumin are mitigated by nanocarriers, surface coatings, and bone-affine composites, though clinical translation remains unproven. This review synthesizes molecular mechanisms, evidence tiers (in vitro to in vivo), and delivery strategies, and distinguishes preventive (coatings/prophylaxis) from therapeutic (adjuvant post-debridement) use cases. Curcumin is a promising adjunct-not a stand-alone therapy-pending standardized biofilm models, bone-level PK/PD, and controlled clinical trials that test defined formulations, doses, and endpoints.</p>","PeriodicalId":29871,"journal":{"name":"Current Reviews in Clinical and Experimental Pharmacology","volume":" ","pages":"281-289"},"PeriodicalIF":2.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147983638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}